All In Biotech

Drug Trial Radar · NCT06633835

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

660

Actual

Start

Sep 19, 2024

Primary completion

Dec 30, 2024

Study completion Jun 30, 2025

Sponsor

Lead sponsor
NovavaxIndustry
Sponsor type
Industry
Collaborators
University of Utah
First posted
Oct 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine

Conditions

  • COVID-19
  • Vaccine-Preventable Diseases
  • SARS CoV 2 Infection

Interventions

  • protein subunit: Novavax COVID-19 vaccineBiological

    Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.

  • Pfizer mRNA COVID-19 vaccineBiological

    Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with solicited systemic reactogenicity symptoms.Time frame: Day 0 to Day 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Utah School of Medicine

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.